[go: up one dir, main page]

SV2009003367A - Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct - Google Patents

Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct

Info

Publication number
SV2009003367A
SV2009003367A SV2009003367A SV2009003367A SV2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A
Authority
SV
El Salvador
Prior art keywords
archostrosystosis
archostrosythosis
arthritis
compounds
chronicacrics
Prior art date
Application number
SV2009003367A
Other languages
English (en)
Inventor
Michael Gaul
Alexander Kim
Searle Lily Lee
Raymond Patch
Dionisios Rentzeperis
Guozhang Xu
Xizhen Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2009003367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SV2009003367A publication Critical patent/SV2009003367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON COMPUESTOS DE FÓRMULA (I): MÉTODOS PARA PREPARAR ESTOS COMPUESTOS, COMPOSICIONES, INTERMEDIARIOS Y DERIVADOS DE LOS MISMOS Y PARA TRATAR UNA CONDICIÓN INCLUYENDO DE MANERA NO EXCLUSIVA, ESPONDILITIS ANQUILOSANTE, ARTEROSCLEROSIS, ARTRITIS (TAL COMO ARTRITIS REUMATOIDE, ARTRITIS INFECCIOSA, ARTRITIS DE LA NIÑEZ, ARTRITIS SORIÁTICA, ARTRITIS REACTIVA), ENFERMEDAD RELACIONADA CON EL HUESOS (INCLUYENDO AQUÉLLAS RELACIONADAS CON LA FORMACIÓN ÓSEA), CÁNCER DE MAMA (INCLUYENDO AQUÉLLOS QUE NO RESPONDEN A LA TERAPIA ANTIESTRÓGENO), TRASTORNOS CARDIOVASCULARES, ENFERMEDAD RELACIONADA CON EL CARTÍLAGO (TAL COMO LESIÓN/PÉRDIDA DEL CARTÍLAGO, DEGENERACIÓN DEL CARTÍLAGO Y AQUÉLLAS RELACIONADAS CON LA FORMACIÓN DE CARTÍLAGO), CONDRODISPLASIA, CONDROSARCOMA, LESIÓN CRÓNICA DE LA ESPALDA, BRONQUITIS CRÓNICA, ENFERMEDAD INFLAMATORIA CRÓNICA DE LAS VÍAS AÉREAS, ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA, DIABETES, TRASTORNOS DE LA HOMEOSTASIS DE LA ENERGÍA, GOTA, SEUDOGOTA, TRASTORNOS LIPÍDICOS, SÍNDROME METABÓLICO, MIELOMA MÚLTIPLE, OBESIDAD, OSTEOARTRITIS, OSTEOGÉNESIS IMPERFECTA, METÁSTASIS ÓSEA OSTEOLÍTICA, OSTEOMALACIA, OSTEOPOROSIS, ENFERMEDAD DE PAGET, ENFERMEDAD PERIODONTAL, POLIMIALGIA REUMÁTICA, SÍNDROME DE REITER, LESIÓN POR ESTRÉS REPETITIVO, HIPERGLUCEMIA, NIVEL ELEVADO DE GLUCOSA EN SANGRE Y RESISTENCIA A LA INSULINA
SV2009003367A 2007-03-07 2009-09-07 Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct SV2009003367A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89345307P 2007-03-07 2007-03-07

Publications (1)

Publication Number Publication Date
SV2009003367A true SV2009003367A (es) 2010-08-10

Family

ID=39535719

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003367A SV2009003367A (es) 2007-03-07 2009-09-07 Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct

Country Status (21)

Country Link
US (2) US7846953B2 (es)
EP (1) EP2129668A1 (es)
JP (1) JP2010520306A (es)
KR (1) KR20090127410A (es)
CN (1) CN101679322A (es)
AR (1) AR065655A1 (es)
AU (1) AU2008222745A1 (es)
BR (1) BRPI0808445A2 (es)
CA (1) CA2679944A1 (es)
CL (1) CL2008000670A1 (es)
CO (1) CO6231008A2 (es)
EA (1) EA200970837A1 (es)
EC (1) ECSP099614A (es)
IL (1) IL200757A0 (es)
MX (1) MX2009009517A (es)
NI (1) NI200900163A (es)
NZ (1) NZ579372A (es)
SV (1) SV2009003367A (es)
TW (1) TW200902508A (es)
UA (1) UA98485C2 (es)
WO (1) WO2008109727A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2008109727A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
HRP20110278T1 (hr) 2007-09-14 2011-05-31 Ortho-Mcneil-Janssen Pharmaceuticals 1',3'-disupstituirani-4-fenil,3,4,5,6-tetrahidro-2h,1'h[1,4']bipiridinil-2'-oni
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
MX2011003691A (es) 2008-10-16 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
US8637558B2 (en) * 2008-12-30 2014-01-28 Industry-Academic Cooperation Foundation, Chosun University Thiazolidinedione derivative and use thereof
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102460165B (zh) * 2009-05-19 2016-08-17 维维雅生物技术公司 用于为血液肿瘤提供离体个体化药物测试的方法
WO2011019558A1 (en) * 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv Methods to measure dissociation rates for ligands that form reversible covalent bonds
US8187871B2 (en) 2009-08-11 2012-05-29 Janssen Pharmaceutica N.V. Co-crystallization of ERR-α with a ligand that forms a reversible covalent bond
US8685891B2 (en) 2009-08-27 2014-04-01 Nuclea Biotechnologies, Inc. Method and assay for determining FAS expression
US8383656B2 (en) * 2009-10-09 2013-02-26 The Ohio State University Research Foundation Thiazolidinedione energy restriction-mimetic agents
CA2805245A1 (en) * 2010-07-28 2012-02-02 Orchid Research Laboratories Ltd. Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012140300A1 (es) * 2011-04-11 2012-10-18 Servicio Andaluz De Salud Compuestos y composiciones para el tratamiento de mieloma múltiple
ES2390303B1 (es) * 2011-04-11 2013-09-16 Servicio Andaluz De Salud Compuestos y composiciones para el tratamiento de mieloma múltiple.
USD688465S1 (en) 2011-06-14 2013-08-27 Telebrands Corp. Hair detangler
WO2013018929A1 (en) 2011-08-04 2013-02-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104302322A (zh) 2012-03-26 2015-01-21 日本化学药品株式会社 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3050573B1 (en) 2013-09-25 2019-12-11 Nippon Chemiphar Co., Ltd. Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3096790B1 (en) 2014-01-21 2019-07-10 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3236903B1 (en) 2014-12-23 2021-04-21 Intellectual Property Associates, LLC Methods and formulations for transdermal administration
WO2017079267A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20250268872A2 (en) * 2019-07-04 2025-08-28 Lead Pharma Holding B.V. Estrogen-related receptor alpha modulators
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
BR112022006906A2 (pt) * 2019-10-18 2022-07-05 Lead Pharma Holding Bv Composto ou sal farmaceuticamente aceitável do mesmo, medicamento e composição farmacêutica

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
JP2001072592A (ja) * 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
JP2008506691A (ja) * 2004-07-14 2008-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−アルファに媒介される疾患の処置のためのアリーリデン
WO2006047269A2 (en) 2004-10-22 2006-05-04 Exelixis, Inc. Pharmaceutical compositions
WO2008109727A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
TW200902507A (en) * 2007-03-07 2009-01-16 Janssen Pharmaceutica Nv Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-α modulators

Also Published As

Publication number Publication date
US20090111855A1 (en) 2009-04-30
TW200902508A (en) 2009-01-16
KR20090127410A (ko) 2009-12-11
AR065655A1 (es) 2009-06-24
NZ579372A (en) 2012-02-24
WO2008109727A1 (en) 2008-09-12
EA200970837A1 (ru) 2010-04-30
ECSP099614A (es) 2009-10-30
WO2008109727A8 (en) 2009-12-17
AU2008222745A1 (en) 2008-09-12
CA2679944A1 (en) 2008-09-12
NI200900163A (es) 2010-07-22
EP2129668A1 (en) 2009-12-09
CN101679322A (zh) 2010-03-24
US7846953B2 (en) 2010-12-07
BRPI0808445A2 (pt) 2014-08-05
CO6231008A2 (es) 2010-12-20
US8344009B2 (en) 2013-01-01
CL2008000670A1 (es) 2008-11-03
JP2010520306A (ja) 2010-06-10
MX2009009517A (es) 2009-09-16
IL200757A0 (en) 2010-05-17
US20110237625A1 (en) 2011-09-29
UA98485C2 (ru) 2012-05-25

Similar Documents

Publication Publication Date Title
SV2009003367A (es) Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
HN2011002933A (es) Inhibidores del canal de potasio medular externo renal
CR11420A (es) Moduladores de gpr40 bifenilo sustituidos
AR065657A1 (es) DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.
CO6341577A2 (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos
NI200900149A (es) COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33715A
AR065656A1 (es) Tiazolidindionas n-alquiladas fenoxi sustituidas como moduladoras del receptor alfa relacionado con estrogeno
PA8799401A1 (es) Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas
CL2008000430A1 (es) Compuestos derivados de heterociclos condensados sustituidos; composicion farmaceutica que comprende a dichos compuestos, utiles para el tratamiento de una o mas condiciones asociadas con receptores adrenergicos a2c, tales como congestion asociada a
AR080207A1 (es) Aminotiazolonas como modulares de los receptores de estrogenos alfa
CL2007001022A1 (es) Compuestos derivados de 1h-indol-2-carboxamida; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de los receptores de h3 tal como obesidad, diabetes tipo ii y
PA8853001A1 (es) 4-azentidinil-1-heteroaril-ciclohexanol antagonista del ccr2
CR20110011A (es) Sustratos que tienen formulaciones con transferibilidad mejorada.
CY1117706T1 (el) Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac
CL2006003737A1 (es) Uso de compuestos derivados de triazina o pirimidina sustituida, para tratar o prevenir enfermedades mediadas por los receptores de prokineticina 2 tales como trastornos gastrointestinales.
ECSP044994A (es) Derivados de diarilcicloalquilo, procedimientos para su preparacion y su utilización como agentes activadores del ppar
BR112015010207A2 (pt) método para promover o crescimento de plantas
UY31117A1 (es) Productos extruidos con enmascaramiento del sabor mejorado
ECSP055985A (es) Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis
AR080206A1 (es) Aminotiazolonas como moduladores del receptor alfa relacionados con estrogeno
UY29962A1 (es) Compuestos calciliticos
UY31033A1 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal
EP2285787A4 (en) 3-SUBSTITUTED PROPANAMINE COMPOUNDS
BRPI0519268A2 (pt) sulfonamido-macrociclos e sais dos mesmos, uma composiÇço farmacÊutica compreendendo esses compostos, o mÉtodo de preparo e uso dos mesmos